The anti-neoplastic effect of doxycycline in osteosarcoma as a metalloproteinase (MMP) inhibitor: a systematic review.
Argyris C HadjimichaelAthanasios F FoukasOlga D SavvidouAndreas F MavrogenisAmanda K PsyrriPanayiotis J Papagelopoulos
Published in: Clinical sarcoma research (2020)
Doxycycline remains a promising chemotherapeutic agent against osteosarcoma via MMP inhibition, showing the need for further in vivo and clinical trials to be carried out in the future.